AIM AIM ImmunoTech Inc.
Price Chart
Executive Summary
AIM ImmunoTech released a video presentation and investor slide deck discussing previously published preclinical data on Ampligen's potential as a prophylactic/early-onset treatment for Ebola virus disease (EVD). The filing contains no new financial data, no guidance, and no material operational changes—it is a routine Regulation FD disclosure of forward-looking scientific commentary.
Actionable Insight
This is a routine awareness-building disclosure with no immediate catalyst. Monitor for any subsequent clinical trial announcements or government funding related to Ebola preparedness, but do not trade on this filing alone.
Key Facts
- Filing is an 8-K under Item 7.01 (Reg FD Disclosure) and 9.01 (Exhibits).
- Company released a video segment and updated investor presentation on Ampligen's preclinical Ebola data.
- Preclinical data cited: 100% protective survival with early Ampligen administration in a lethal Ebola mouse model.
- Ampligen has orphan drug designation from both FDA and EMA for Ebola virus disease.
- No financial results, guidance, or material agreements were disclosed.
- Market cap is approximately $12M; the company is a pre-revenue clinical-stage biotech.
Financial Impact
No financial impact disclosed; filing is purely informational.
Risk Factors
- Preclinical results may not translate to human efficacy.
- Company has no approved products and limited cash runway (market cap ~$12M).
- No new funding or partnership announced to advance the Ebola program.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027210 |
| Exhibit: ex99-1.htm | 0001493152-26-027210 |
| Document: 0001493152-26-027210-index-headers.html | 0001493152-26-027210 |
| Document: 0001493152-26-027210-index.html | 0001493152-26-027210 |
| Document: 0001493152-26-027210.txt | 0001493152-26-027210 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $0.4543 awaiting T+1 | awaiting T+1 | — | $0.4100 (+9.75%) |
|
Jun 10, 2026
4d ago
|
424B5
| $0.4477 awaiting T+1 | awaiting T+1 | — | $0.4100 (+8.42%) |
|
Jun 8, 2026
6d ago
|
Press Release
| $0.4589 awaiting T+1 | awaiting T+1 | — | $0.4100 (−10.66%) |
|
Jun 4, 2026
10d ago
|
8-K
| $0.5900 $0.5200 | ▼ −11.86% | ▼ −9.27% | $0.4100 (−30.51%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $0.9000 $0.8300 | ▼ −7.78% | ▼ −7.92% | $0.4100 (−54.44%) |
|
May 21, 2026
24d ago
|
8-K
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4100 (−70.83%) |
|
May 21, 2026
24d ago
|
424B5
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4100 (−70.83%) |
|
May 20, 2026
25d ago
|
Press Release
| $0.2500 $0.2400 | ▲ +4.00% | ▲ +4.19% | $0.4100 (−64.00%) |
|
May 19, 2026
26d ago
|
424B5
| $0.2500 $0.2400 | ▼ −4.00% | ▼ −4.19% | $0.4100 (+64.00%) |
|
May 19, 2026
26d ago
|
8-K
| $0.4100 $0.2500 | ▼ −39.02% | ▼ −40.06% | $0.4100 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access